Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma

Bone Marrow Transplantation volume 51, pages 432–434 (2016)Cite this article

Subjects

Adult T-cell leukemia/lymphoma (ATLL) has an aggressive clinical course, and the prognosis of acute- and lymphoma-type ATLL is extremely poor, even when treated with combination chemotherapy.1 Previous reports have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a promising therapy frequently associated with long-term survival.2, 3

Mogamulizumab (Moga) is a humanized defucosylated anti-CC chemokine receptor 4 (CCR4) monoclonal antibody that markedly enhances antibody-dependent cellular cytotoxicity. Moga is effective for newly diagnosed and previously treated CCR4-positive ATLL.4, 5 Therefore, Moga-containing induction therapy may lead to better disease control at the time of allo-HSCT. CCR4 is also expressed on regulatory T cells (Tregs) that induce anergic and suppressive allogeneic responses.6 Decreased Treg activity mediated by Moga may be associated with an increased frequency of severe GvHD. However, little information exists regarding the effects of Moga in allo-HSCT in ATLL patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458–5464.

    Article  CAS  Google Scholar 

  2. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010; 116: 1369–1376.

    Article  CAS  Google Scholar 

  3. Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, Harada M et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant 2011; 46: 116–118.

    Article  CAS  Google Scholar 

  4. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837–842.

    Article  CAS  Google Scholar 

  5. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 2015; 169: 672–682.

    Article  CAS  Google Scholar 

  6. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001; 194: 847–853.

    Article  CAS  Google Scholar 

  7. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One 2009; 4: e4420.

    Article  Google Scholar 

  8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–1756.

    Article  CAS  Google Scholar 

  9. Okamoto T, Nishimura Y, Yamada S, Yamada S, Itoh T, Mori A et al. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. Acta Haematol 2000; 104: 128–130.

    Article  CAS  Google Scholar 

  10. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S . Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389–399.

    Article  CAS  Google Scholar 

  11. Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 2004; 10: 552–560.

    Article  CAS  Google Scholar 

  12. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010; 120: 1479–1493.

    Article  CAS  Google Scholar 

  13. Motohashi K, Suzuki T, Kishimoto K, Numata A, Nakajima Y, Tachibana T et al. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation. Int J Hematol 2013; 98: 258–260.

    Article  Google Scholar 

  14. Ito Y, Miyamoto T, Chong Y, Aoki T, Kato K, Akashi K et al. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation. Bone Marrow Transplant 2013; 48: 998–999.

    Article  CAS  Google Scholar 

  15. Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 2012; 119: 2141–2148.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, National Kyushu Cancer Center, National Hospital Organization, Fukuoka, Japan

    S Haji, I Choi, Y Suehiro, K Toyoda, M Tsuda, A Takamatsu, Y Nakashima, N Uike & Y Abe

  2. Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan

    J Kiyasu & H Miyoshi

  3. Department of Hematology, Iizuka Hospital, Fukuoka, Japan

    J Kiyasu

  4. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    M Shiratsuchi

  5. Department of Hematology, National Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan

    S Yamasaki

Authors
  1. S Haji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Kiyasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Suehiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Toyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Shiratsuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. N Uike
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Y Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Abe.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haji, S., Kiyasu, J., Choi, I. et al. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma. Bone Marrow Transplant 51, 432–434 (2016). https://doi.org/10.1038/bmt.2015.254

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.254

This article is cited by

Search

Advanced search

Quick links